Erlotinib, gefitinib (1st generation), and afatinib (2nd generation) have intracranial activity in NSCLC patients with EGFR mutations, with objective response rates ranging from 60–80%25. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.